Загрузка...

Aberrant expression of ERG promotes resistance to combined PI3K and AR pathway inhibition through maintenance of AR target genes

Based on our previous work defining the molecular rationale for combined targeting of the PI3K and AR pathways in PTEN loss prostate cancer, the first clinical trial was recently reported demonstrating a significant benefit for combination therapy in patients with metastatic prostate cancer. In this...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Cancer Ther
Главные авторы: Mao, Ninghui, Gao, Dong, Hu, Wenhuo, Hieronymus, Haley, Wang, Shangqian, Lee, Young Sun, Lee, Cindy, Choi, Danielle, Gopalan, Anuradha, Chen, Yu, Carver, Brett S
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726496/
https://ncbi.nlm.nih.gov/pubmed/31296553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-1386
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!